Brought to you by 
ImVisioN licenses MannKind's patents
18 Jul 2006
Executive Summary
ImVisioN GMBH (biopharma focused on cancer and diabetes) licensed exclusive worldwide rights from German biotech MannKind (lymphatic delivery of allergy therapeutics) to patents related to the administration of an allergen directly into a lymph node to modulate or eliminate an allergic condition and reduce the potential for side effects.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ImVisioN licenses MannKind's patents
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice